StreetInsider.com News Articles

Form 8-K Bausch & Lomb Corp For: Oct 11

Tue, 13 Oct 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20261013/27176400.html

Form 8-K Bausch & Lomb Corp For: Oct 11

Tue, 13 Oct 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20261013/27176400.html

Bausch Health study shows modest gains in cirrhosis care adherence

Mon, 12 Oct 2026 08:04:18 -0400

Bausch Health Companies Inc. (NYSE: BHC) and its gastroenterology unit, Salix Pharmaceuticals, announced results from a six-month multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management, with findings to be presented at the American College of Gastroenterology Annual Scientific Meeting in Nashville, Tennessee, running October 9-14, 2026.

The study, conducted across five community gastroenterology practices, included 4,251 patients with cirrhosis and tracked adherence to five key performance indicators over the pilot period.

Results showed incremental improvements across all tracked metrics. Office visit adherence rose from 46.9% to 51.1%, a 9.0% relative improvement. Laboratory monitoring adherence increased from 61.5% to 63.5%,

Bausch Health study shows modest gains in cirrhosis care adherence

Mon, 12 Oct 2026 08:04:18 -0400

The study, conducted across five community gastroenterology practices, included 4,251 patients with cirrhosis and tracked adherence to five key performance indicators over the pilot period.

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

Mon, 12 Oct 2026 08:00:00 -0400

LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, taking place October

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

Mon, 12 Oct 2026 08:00:00 -0400

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Mon, 12 Oct 2026 06:45:00 -0400

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb.

Appio was appointed chairman of the Bausch + Lomb Board of Directors in August 2026. The Board believes Appio’s deep knowledge of the business, global leadership experience and longstanding connection to Bausch + Lomb

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Mon, 12 Oct 2026 06:45:00 -0400

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Mon, 12 Oct 2026 06:45:00 -0400

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Mon, 12 Oct 2026 06:45:00 -0400

RBC Capital Reiterates Sector Perform Rating on Bausch Health Companies (BHC)

Thu, 08 Oct 2026 04:31:45 -0400

RBC Capital analyst Doug Miehm reiterated a Sector Perform rating and $9.00 price target on Bausch Health Companies (NYSE: BHC).

The analyst comments "BHC will report Q3/26 results after market close on October 28, following BLCO's Q3 results (bmo) on the same day. We estimate Q3/26 consolidated revenue of $2.79B (FactSet consensus: $2.75B) and adj. EBITDA of $1,037MM, excluding $36MM MI associated with the BLCO holding (vs. consensus: $1,051MM). Key areas of focus include: the guided H2 headwinds on the Q2/26 earnings call; updates on the ongoing Xifaxan patent litigation; Solta Medical margin durability post- Shibo integration; the delayed Aplenzin generic

Bausch + Lomb eyes 2027 trial start for oral dry AMD drug

Tue, 06 Oct 2026 16:30:21 -0400

Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a meeting with the U.S. Food and Drug Administration (FDA).

According to a company press release, the FDA was supportive in principle of the proposed initial study design, which will evaluate how the medicine behaves in the body and assess its safety. Results from that initial study are expected, barring unexpected findings, to support advancement into a Phase 2 study in patients with dry AMD who have not yet developed advanced retinal damage. Bausch + Lomb

Bausch + Lomb eyes 2027 trial start for oral dry AMD drug

Tue, 06 Oct 2026 16:30:21 -0400

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Tue, 06 Oct 2026 16:30:00 -0400

BL1243 (tonabersat) is being developed as a potential oral treatment for patients with earlier-stage dry AMD, where treatment options remain limited
Clinical development program expected to begin in 2027

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA).